Trials Sponsors Conditions Drugs Pricing

Conditions

Infertility in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle

Outcome Measures

Primary Outcomes (1)

Number of fertilised (2 pronuclei [2PN]) oocytes at 19±2 hours after insemination

Interventions

Fyremadel, 0,25 mg/0,5 ml oplossing voor injectie in voorgevulde spuitType not reported

Decapeptyl 0,1 mg/1 ml, oplossing voor injectieType not reported

MenopurType not reported

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Registry intervention entries

These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.

Formulated product
Fyremadel, 0,25 mg/0,5 ml oplossing voor injectie in voorgevulde spuit
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INJECTION
View registry record
Formulated product
Decapeptyl 0,1 mg/1 ml, oplossing voor injectie
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INJECTION
View registry record
Formulated product
Menopur
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INJECTION
View registry record
Formulated product
Ovitrelle 250 micrograms/0.5 mL solution for injection in pre-filled syringe
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INJECTION
View registry record
Formulated product

Ingredients named in source formulations

The registry names these ingredients. The formulation’s exact chemical form has not been confirmed.

Fyremadel, 0,25 mg/0,5 ml oplossing voor injectie in voorgevulde spuit
Named ingredient: ganirelix
View registry record
Decapeptyl 0,1 mg/1 ml, oplossing voor injectie
Named ingredient: Triptorelin acetate
View registry record
Menopur
Named ingredient: Menotrophin
View registry record
Ovitrelle 250 micrograms/0.5 mL solution for injection in pre-filled syringe
Named ingredient: Choriogonadotropin alfa
View registry record
REKOVELLE 72 micrograms/2.16 mL solution for injection in a pre-filled pen
Named ingredient: follitropin delta
View registry record
Menopur
Named ingredient: Menotrophin
View registry record
Ovitrelle 250 micrograms solution for injection in pre-filled pen

Eligibility Criteria

Sexfemale

Age GroupsAdult (18-64)

You may qualify if:

Informed Consent Form signed prior to screening evaluations.
In good physical and mental health as judged by the investigator, and willing and able to comply with the trial protocol.
Pre-menopausal females between the ages of 18 and 40 years. The subjects must be at least 18 years (including the 18th birthday) when they sign the informed consent and no more than 40 years (up to the day before the 41st birthday) at the time of randomisation.

Sponsors & Collaborators

Ferring Pharmaceuticals A/S
Industrylead

Study Sites (4)

Azienda Provinciale Per I Servizi Sanitari

Trento, 38123, Italy

Arne Luehwink0464582766 arne.luehwink@apss.tn.it

Hospital Universitario Y Politécnico La Fe

Valencia, 46026, Spain

Jose Maria Rubio Rubio+34666496016 jmrubior@yahoo.es

Ginefiv S.L.

Madrid, 28043, Spain

Laura Blasco Gastón900908988

Central Study Contacts

Global Translational & Clinical R&D

+4588338834 DK0-Disclosure@ferring.com

Study Design

Study Type: interventional

Study Record Dates

First Submitted

July 15, 2022

Source record

Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: 2022-500308-23-00
Data provider: European Medicines Agency (EMA)
Normalization version: ctis-v1

Open registry record

Source retrieved: 2026-10-31 03:06:52 UTC

Locations

ES(3)GB(0)

MENOPUR and REKOVELLE in Women UnderGoing an assisted reproductive technology cycle

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

Conditions

Outcome Measures

Primary Outcomes (1)

Interventions

Registry intervention entries

Ingredients named in source formulations

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (4)

Central Study Contacts

Study Design

Study Record Dates

Source record

Locations

You may not qualify if:

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Conditions

Outcome Measures

Primary Outcomes (1)

Interventions

Registry intervention entries

Ingredients named in source formulations

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (4)

Central Study Contacts

Study Design

Study Record Dates

Source record

Locations

You may not qualify if: